Afric Phar has been acquired by Pharma Capital
Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.
Founded in 1966, Afric Phar is a privately owned Moroccan pharmaceutical company that has evolved into a fully integrated operation, spanning production, marketing, sales and distribution. As one of the first pharmaceutical companies established entirely by Moroccan pharmacists, it has built a strong reputation within the local market. Specializing in the import, manufacturing and distribution of generic drugs, Afric Phar serves a wide range of therapeutic areas. The company has also expanded its product portfolio and market reach through strategic partnerships with leading European and multinational laboratories under licensing agreements.
Pharma Capital, part of the Sefrioui group, is a Moroccan joint-stock company. The company focuses on investments in the pharmaceutical sector and was established as a dedicated vehicle to execute this specific investment strategy.
The Chaoui family, founders and owners of Afric Phar, have been instrumental to the company’s success, guiding it through decades of growth and innovation in Morocco’s pharmaceutical sector.
Oaklins’ team in Morocco acted as the sell-side advisor for a group of the selling shareholders, responsible for structuring, executing and negotiating the transaction.
Prata med transaktionsteamet
Relaterade affärer
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Lär dig merbioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Lär dig merBanook, backed by Motion Equity, has acquired Fluidda
Banook Group has acquired Fluidda NV, marking a strategic expansion into advanced in-silico trials and respiratory disease modeling. Combining Banook’s expertise in cardiac safety and clinical data services with Fluidda’s AI-driven respiratory analytics creates a powerful, integrated platform. This deal strengthens Banook’s position in the contract research organization (CRO) sector, offering pharmaceutical clients broader, technology-enabled solutions to drive drug development and reduce costs.
Lär dig mer